Researchers report on the sweet side of snake venom toxins

NewsGuard 100/100 Score

A bite from a lancehead snake can be fatal. Species in the family, found throughout Central and South America, have venom that can disrupt blood clotting and cause hemorrhage, strokes and kidney failure.

Solange Serrano, a researcher at the Laboratory of Applied Toxicology at the Instituto Butantan in Sao Paulo, Brazil, studies the protein toxins in venom from these snakes. In a recent article in the journal Molecular & Cellular Proteomics, scientists from Serrano's laboratory, in collaboration with researchers at the University of New Hampshire, report on the sweet side of snake venom toxins.

The researchers looked at glycans, a group of sugar molecules attached in a complex chain, often with many branches, that can be attached to proteins. According to Serrano, most proteins in lancehead venom are modified with glycans, which can affect the proteins' folding, stability and binding. But very little is known about glycan structure in the snakes' venom.

Serrano's graduate student Debora Andrade-Silva visited the laboratory of glycomics expert Vernon Reinhold in New Hampshire to learn techniques for structural characterization of glycans. While there, Andrade-Silva and colleagues characterized the structure of 60 glycan chains in eight lancehead, or Bothrops, species' venoms. The researchers isolated the glycans and analyzed them by mass spectrometry, breaking down each complex molecule into smaller, simpler ions. By piecing together the spectra of many such ions, it was possible to tell which sugars were present and how they were linked into tree-like glycan structures.

Lancehead venom contains nearly 100 milligrams of protein per milliliter of liquid. At this concentration, protein solutions tend to become very viscous or form gels. Analyzing the structures of glycans attached to the proteins, the researchers found that a disproportionate number were tipped with sialic acid, a sugar with a negative charge. "Glycans containing sialic acid may help in venom solubility and increase toxin half-life," said Serrano. Sialic acid on a toxic enzyme may also bind to host proteins called siglecs, pulling the enzyme closer to target cells for greater effect; this has been observed in other types of venom.

While Serrano's group conducts basic research on venom composition, the applications are very close to home. Another department of the Instituto Butantan produces most of the antivenom available in Brazil. Serrano said she hopes that basic research into venom toxins will help researchers develop improved treatments for envenomation.

"The antivenoms do a reasonable job, but they are not so good at neutralizing the local effects of snakebite," including swelling, hemorrhage and necrosis, Serrano said. These effects can be severe enough that doctors must sometimes amputate bitten limbs. Better understanding how venom differs between snake species could improve the efficacy of antivenom treatment. Andrade-Silva and Serrano are now working to map the structures from the glycan inventory back onto the proteins they modify. Because some venom proteins have been repurposed as medicines, knowing more about how glycosylation helps each protein fold, hold its shape, and attach to binding partners may further have applications in biotechnology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer